RT Journal Article
SR Electronic
T1 Pembrolizumab Yields Lasting Merkel Cell Carcinoma Responses
JF Cancer Discovery
JO Cancer Discov
FD American Association for Cancer Research
SP 566
OP 566
DO 10.1158/2159-8290.CD-NB2016-050
VO 6
IS 6
YR 2016
UL http://cancerdiscovery.aacrjournals.org/content/6/6/566.1.abstract
AB In a phase II single-arm study, the PD-1 checkpoint inhibitor pembrolizumab effectively shrank tumors and prolonged survival in more than half of patients with Merkel cell carcinoma. Responses were significantly more durable that those typically seen with chemotherapy.